DuP 937（替洛蒽醌）用于非小细胞肺癌的II期试验。加拿大国家癌症研究所临床试验组的一项研究。 - Suppr

A phase II trial of DuP 937 (Teloxantrone) in non-small cell lung cancer. A study of the NCIC Clinical Trials Group.

Gregg R W, Kaizer L, Fine S, Gelmon K, Wielgosz G, Eisenhauer E

Department of Radiation Oncology, Dalhousie University, Halifax, N.S., Canada.

Ann Oncol. 1993 Sep;4(8):693-4. doi: 10.1093/oxfordjournals.annonc.a058627.

Abstract

摘要

Ann Oncol. 1993 Sep;4(8):693-4. doi: 10.1093/oxfordjournals.annonc.a058627.

Invest New Drugs. 1992 Apr;10(1):29-30. doi: 10.1007/BF01275476.

Invest New Drugs. 1993 May-Aug;11(2-3):235-7. doi: 10.1007/BF00874163.

Ann Oncol. 1993 Sep;4(8):695-6. doi: 10.1093/oxfordjournals.annonc.a058628.

J Natl Cancer Inst. 1993 Mar 3;85(5):388-94. doi: 10.1093/jnci/85.5.388.

Invest New Drugs. 1993 Nov;11(4):301-8. doi: 10.1007/BF00874428.

J Natl Cancer Inst. 1993 Mar 3;85(5):346-7. doi: 10.1093/jnci/85.5.346.

Can J Cardiol. 1995 May;11(5):419-22.

Invest New Drugs. 1993 Nov;11(4):337-41. doi: 10.1007/BF00874435.

Invest New Drugs. 2002 Aug;20(3):339-42. doi: 10.1023/a:1016293527755.

20分钟写一篇综述，助力文献阅读效率提升50倍。

大模型驱动的PubMed中文搜索引擎

学术文献翻译模型，支持多种主流文档格式。